Key Highlights

  • EDX Medical Group PLC (LSE:EDX) founder and chief scientific officer Professor Sir Christopher Evans will present at a London private investor evening on 11 November 2026.
  • The company is preparing to launch employee health screening in the fourth quarter of 2026, with agreements in principle covering around 14,000 employees at three large UK employers.
  • EDX signed a three-year health screening deal with Arnold Clark Group in September.
  • The group aims to screen 25,000 men for prostate cancer by the end of 2026 through the Scottish Prostate Cancer Testing Initiative.
  • EDX raised around £2.7 million at 14p in August and reported FY2026 Revenue of around £330,000 with a loss of about £5.7 million.

Why EDX Medical Is in Focus Today

EDX Medical Group PLC (LSE:EDX) is drawing interest from healthcare investors on the FTSE AIM All-Share as of 5 November 2026. The Cambridge-based diagnostics company announced this week that its founder, the biotech Entrepreneur Professor Sir Christopher Evans, will present at a private investor evening in London on 11 November. The presentation comes at a pivotal moment, with the company preparing to begin testing under its new employee health screening service before the end of the year.

EDX moved its listing from the Aquis Stock Exchange to AIM in May 2026, increasing its visibility among UK investors. Since then, a steady flow of commercial updates, from workplace screening deals to NHS deployments of its rapid pneumonia test, has made LSE:EDX a regular topic of conversation on investor forums and social media.

What EDX Medical Does

EDX Medical develops and supplies digital diagnostic products and services designed to improve the early detection and treatment of major diseases, including cancer, cardiovascular conditions and infectious diseases. Its tests aim to support personalised treatment decisions. Key offerings include prostate cancer testing, the BC95 bowel cancer biomarker service, which combines early detection with hereditary risk analysis, and a rapid pneumonia test now being used in NHS clinical practice at Addenbrooke's Hospital's intensive care unit.

The Workplace Screening Opportunity

The most important near-term growth driver for EDX Medical Group PLC (LSE:EDX) is its employee health screening service. The company has developed screening panels that combine general health checks with biomarker testing for conditions such as cancer, cardiovascular disease and metabolic disorders. In October, it said it is expanding the service to assess the risk of hundreds of diseases from one or two samples, including conditions that may not yet produce symptoms.

EDX has reached agreements in principle with three large UK employers covering around 14,000 employees, subject to final documentation, with testing expected to start in the fourth quarter of 2026. In September, it signed a three-year agreement with Arnold Clark Group, one of the UK's largest car retailers, to provide health and wellbeing screening to its employees. Two further large companies have approached EDX about the service. Management has previously indicated that the screening service could generate more than £2 million of revenue.

EDX will deploy its own nurses and logistics managers to employer sites. Employers do not receive individual results, and reporting is designed to comply with data protection rules. The workplace model allows the company to reach large numbers of people without relying on individuals to arrange tests themselves.

Prostate Cancer Testing at Scale

EDX leads the Scottish Prostate Cancer Testing Initiative, which entered its second phase in August. The company aims to screen 25,000 men aged 40 to 70 by the end of 2026. It has said that many men identified with prostate cancer through the programme had no symptoms and were unaware of the disease, highlighting the potential value of targeted screening.

Financial Position

For the year ended 31 March 2026, EDX Medical Group PLC (LSE:EDX) reported revenue of around £330,000 and a loss of about £5.7 million as it invested in commercial growth and laboratory capabilities. It raised around £5.5 million during that year. In February 2026, it raised £3.5 million from existing high net worth shareholders at 14p, and in August it raised a further £2.7 million at 14p to support the expansion of the workplace screening service. Professor Michael Owen was recently appointed non-executive chairman, succeeding Jason Holt.

Risks to Consider

EDX is an early-stage commercial company with modest revenue and ongoing losses, so it remains dependent on external funding until sales scale. Agreements in principle still need to be finalised, and the pace of employee uptake is uncertain. Competition in health screening and diagnostics is significant, and NHS adoption can be slow.

What Investors Are Watching Next

The immediate event for LSE:EDX is Sir Christopher Evans' investor presentation on 11 November 2026, where investors will listen for updates on screening contracts and revenue timing. The key operational milestone is the start of employee testing in the fourth quarter, along with finalisation of agreements with the three large employers and any new corporate clients.

Investors will also watch progress towards 25,000 prostate cancer screenings, wider NHS adoption of the pneumonia test, uptake of the BC95 service and interim results for the six months to September. Successful delivery could help EDX Medical Group PLC (LSE:EDX) establish itself as a growing diagnostics player on the FTSE AIM All-Share.